Abstract Details

Title Final results from the BETAPAEDIC study of interferon beta-1b for treatment-naive pediatric patients with relapsing-remitting MS

Topic Multiple Sclerosis

Presentation(s) P1 - (-)

Poster/Presentation
Number 346

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Jutta Gaertner, MD PRESENTER	Dr. Gaertner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Gaertner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Gaertner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gaertner has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Biogen.
Wolfgang Brueck, PhD (Zentrum Pathologie)	Dr. Brueck has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Joerg-Peter Bugge, PhD (Bayer Schering Pharma AG Berlin)	No disclosure on file

��ɫ��